{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:59:45Z","timestamp":1790873985009,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaut.2024.103243","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T02:05:56Z","timestamp":1716516356000},"page":"103243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Elevated unphosphorylated STAT1 and IRF9 in T and B cells of primary sj\u00f6gren's syndrome: Novel biomarkers for disease activity and subsets"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-1564","authenticated-orcid":false,"given":"Jacob","family":"Ritter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Szelinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Aue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Luisa","family":"Stefanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Rincon-Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Duc","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia C.","family":"Lino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2024.103243_bib1","doi-asserted-by":"crossref","unstructured":"X. Mariette, L.A. Criswell, Primary Sj\u00f6gren\u2019s syndrome, N. Engl. J. Med. (2018); 379:96-97.","DOI":"10.1056\/NEJMc1804598"},{"issue":"6","key":"10.1016\/j.jaut.2024.103243_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105406","article-title":"Current and future treatment in primary Sj\u00f6gren's syndrome - a still challenging development","volume":"89","author":"Ritter","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaut.2024.103243_bib3","doi-asserted-by":"crossref","unstructured":"M.G.A. Broeren, J.J. Wang, G. Balzaretti, P. Groenen, B.D.C. van Schaik, T. Chataway, et al., Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sj\u00f6gren\u2019s syndrome, Ann. Rheum. Dis. (2022); 81(5):644-652.","DOI":"10.1136\/annrheumdis-2021-221604"},{"key":"10.1016\/j.jaut.2024.103243_bib4","article-title":"Autoimmune B cell repertoire in a mouse model of Sj\u00f6gren's syndrome","volume":"12","author":"S\u00e1ez","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2024.103243_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12016-020-08793-7","article-title":"Immunobiology of T Cells in Sj\u00f6gren's syndrome","volume":"60","author":"Yao","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2024.103243_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.41558","article-title":"Interleukin-7\/Interferon Axis drives T cell and salivary gland epithelial cell interactions in Sj\u00f6gren's syndrome","volume":"73","author":"Rivi\u00e8re","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2024.103243_bib7","first-page":"1988","article-title":"CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren's syndrome","volume":"7","author":"Jin","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"6146","key":"10.1016\/j.jaut.2024.103243_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1126\/science.1241680","article-title":"T follicular helper cell dynamics in germinal centers","volume":"341","author":"Shulman","year":"2013","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jaut.2024.103243_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren's syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2024.103243_bib10","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sj\u00f6gren's syndrome patients from healthy control subjects","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2024.103243_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681941","article-title":"The transcriptome of paired major and minor salivary gland tissue in patients with primary Sj\u00f6gren's syndrome","volume":"12","author":"Verstappen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103243_bib12","doi-asserted-by":"crossref","unstructured":"X. Chen, S. Jiang, Z. Zhou, X. Xu, S. Ying, L. Du, et al., Increased expression of interleukin-21-inducible genes in minor salivary glands are associated with primary Sj\u00f6gren\u2019s syndrome disease characteristics, Rheumatology (2020); 60 (6): 2979-2989.","DOI":"10.1093\/rheumatology\/keaa695"},{"issue":"4","key":"10.1016\/j.jaut.2024.103243_bib13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/art.23404","article-title":"Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus","volume":"58","author":"Biesen","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2024.103243_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj\u00f6gren's syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.jaut.2024.103243_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2024.103243_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2017.00029","article-title":"Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses","volume":"8","author":"Majoros","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2024.103243_bib17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3389\/fimmu.2018.01135","article-title":"A positive feedback amplifier circuit that regulates interferon (IFN)-Stimulated gene expression and controls type I and type II IFN responses","volume":"9","author":"Michalska","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103243_bib18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2019.07.007","article-title":"Differential activation of the transcription factor IRF1 underlies the distinct immune responses elicited by type I and type III interferons","volume":"51","author":"Forero","year":"2019","journal-title":"Immunity"},{"issue":"23","key":"10.1016\/j.jaut.2024.103243_bib19","doi-asserted-by":"crossref","first-page":"9373","DOI":"10.1073\/pnas.0903487106","article-title":"Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes","volume":"106","author":"Cheon","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"20","key":"10.1016\/j.jaut.2024.103243_bib20","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/emboj.2013.203","article-title":"IFN\u03b2-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage","volume":"32","author":"Cheon","year":"2013","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.jaut.2024.103243_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminoncol.2014.02.002","article-title":"Interferons and their stimulated genes in the tumor microenvironment","volume":"41","author":"Cheon","year":"2014","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.jaut.2024.103243_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cr.2008.41","article-title":"Roles of unphosphorylated STATs in signaling","volume":"18","author":"Yang","year":"2008","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.jaut.2024.103243_bib23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2024.103243_bib24","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2024.103243_bib25","author":"Sciences"},{"issue":"1","key":"10.1016\/j.jaut.2024.103243_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2024.103243_bib27","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2024.103243_bib28","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/rheumatology\/keaa187","article-title":"Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility","volume":"59","author":"Aue","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jaut.2024.103243_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/eji.202149575","article-title":"Altered increase in STAT1 expression and phosphorylation in severe COVID-19","volume":"52","author":"Rincon-Arevalo","year":"2022","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2024.103243_bib30","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/art.42265","article-title":"Variability of primary Sj\u00f6gren's syndrome is driven by interferon-\u03b1 and interferon-\u03b1 blood levels are associated with the class II HLA-DQ locus","volume":"74","author":"Trutschel","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2024.103243_bib31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sj\u00f6gren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.jaut.2024.103243_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12662","article-title":"Transcription profiling of peripheral B cells in antibody-positive primary Sj\u00f6gren's syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature","volume":"87","author":"Imgenberg-Kreuz","year":"2018","journal-title":"Scand. J. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2024.103243_bib33","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/art.39204","article-title":"Molecular subsetting of interferon pathways in Sj\u00f6gren's syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2024.103243_bib34","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/eji.201747213","article-title":"Aberrant cell signalling in PBMCs upon IFN-\u03b1 stimulation in primary Sj\u00f6gren's syndrome patients associates with type I interferon signature","volume":"48","author":"Davies","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2024.103243_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.854183","article-title":"Aberrant signaling of immune cells in Sj\u00f6gren's syndrome patient subgroups upon interferon stimulation","volume":"13","author":"Sarkar","year":"2022","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.jaut.2024.103243_bib36","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1093\/emboj\/19.15.4111","article-title":"How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene","volume":"19","author":"Chatterjee-Kishore","year":"2000","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.jaut.2024.103243_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/excr.2001.5405","article-title":"Cell type-specific and tyrosine phosphorylation-independent nuclear presence of STAT1 and STAT3","volume":"272","author":"Meyer","year":"2002","journal-title":"Exp. Cell Res."},{"issue":"10","key":"10.1016\/j.jaut.2024.103243_bib38","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1242\/jcs.200659","article-title":"Unphosphorylated STAT1 represses apoptosis in macrophages during Mycobacteriumtuberculosis infection","volume":"130","author":"Yao","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jaut.2024.103243_bib39","first-page":"1","article-title":"Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19","author":"Jeong","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.jaut.2024.103243_bib40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI30065","article-title":"IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice","volume":"118","author":"Thibault","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2024.103243_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal centers","volume":"40","author":"Victora","year":"2022","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2024.103243_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.immuni.2023.02.003","article-title":"B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection","volume":"56","author":"Chen","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jaut.2024.103243_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/cei.12703","article-title":"A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sj\u00f6gren's syndrome and systemic lupus erythematosus","volume":"183","author":"Szab\u00f3","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2024.103243_bib44","doi-asserted-by":"crossref","unstructured":"S. Liu, Y. Yang, L. Zeng, L. Wang, C. He, Z. Chen, et al., TOX promotes follicular helper T cell differentiation in patients with primary Sj\u00f6gren\u2019s syndrome, Rheumatology (2022); 62(2):946-957.","DOI":"10.1093\/rheumatology\/keac304"},{"issue":"6","key":"10.1016\/j.jaut.2024.103243_bib45","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","article-title":"Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA","volume":"52","author":"Soni","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jaut.2024.103243_bib46","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"4","key":"10.1016\/j.jaut.2024.103243_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"10320","key":"10.1016\/j.jaut.2024.103243_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaut.2024.103243_bib49","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jaut.2024.103243_bib50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.rdc.2016.03.009","article-title":"Sj\u00f6gren syndrome: why Do clinical trials fail?","volume":"42","author":"Fox","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841124000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T20:30:38Z","timestamp":1720816238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841124000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"alternative-id":["S0896841124000775"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103243","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated unphosphorylated STAT1 and IRF9 in T and B cells of primary sj\u00f6gren's syndrome: Novel biomarkers for disease activity and subsets","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2024.103243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103243"}}